What is Emergent Biosolutions's long-term debt?

Emergent Biosolutions (EBS) reported long-term debt of $573.6M in Q1 2026.

How has Emergent Biosolutions's long-term debt changed year-over-year?

Emergent Biosolutions's long-term debt decreased by 13.8% year-over-year, from $665.7M to $573.6M.

What is the long-term trend for Emergent Biosolutions's long-term debt?

Over 5 years (2020 to 2025), Emergent Biosolutions's long-term debt has grown at a -7.4% compound annual growth rate (CAGR), from $841M to $572.1M.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Emergent Biosolutions EBS Long-Term Debt

Long-Term Debt at other companies

Thermo Fisher ScientificTMO

$42.95B+26.4%

Regeneron PharmaceuticalsREGN

$1.99B+0.1%

AMP

Amphastar PharmaceuticalsAMPH

$609.8M+1.0%

Amneal Pharmaceuticals, Inc.AMRX

$2.57B+19.1%

West Pharmaceutical ServicesWST

$202.8M+0.1%

Medline, Inc. MDLN

$12.5B—

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's long-term debt?: Emergent Biosolutions (EBS) reported long-term debt of $573.6M in Q1 2026.
How has Emergent Biosolutions's long-term debt changed year-over-year?: Emergent Biosolutions's long-term debt decreased by 13.8% year-over-year, from $665.7M to $573.6M.
What is the long-term trend for Emergent Biosolutions's long-term debt?: Over 5 years (2020 to 2025), Emergent Biosolutions's long-term debt has grown at a -7.4% compound annual growth rate (CAGR), from $841M to $572.1M.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.